Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
about
Effect of rifampin and nelfinavir on the metabolism of methadone and buprenorphine in primary cultures of human hepatocytesIs levorphanol a better option than methadone?A review of pharmacological interactions between HIV or hepatitis C virus medications and opioid agonist therapy: implications and management for clinical practiceNephrotoxicity of methadone: a systematic reviewInsights into CYP2B6-mediated drug-drug interactionsThe pharmacokinetics of methadone and its metabolites in neonates, infants, and childrenThe pharmacokinetics of methadone in adolescents undergoing posterior spinal fusion.Methadone initiation and rotation in the outpatient setting for patients with cancer painDrug interactions with new and investigational antiretrovirals.QT interval screening in methadone maintenance treatment: report of a SAMHSA expert panel.The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of substance use and related disorders. Part 2: Opioid dependence.Contribution of cytochrome P450 and ABCB1 genetic variability on methadone pharmacokinetics, dose requirements, and responseMethadone: a substrate and mechanism-based inhibitor of CYP19 (aromatase).A modeling and simulation approach to characterize methadone QT prolongation using pooled data from five clinical trials in MMT patients.Differential activation of pregnane X receptor and constitutive androstane receptor by buprenorphine in primary human hepatocytes and HepG2 cells.Stereo-selective metabolism of methadone by human liver microsomes and cDNA-expressed cytochrome P450s: a reconciliationPharmacokinetics of methadone.Assessment of a candidate marker constituent predictive of a dietary substance-drug interaction: case study with grapefruit juice and CYP3A4 drug substrates.Prediction of human pharmacokinetics--gut-wall metabolism.Methadone pharmacokinetics are independent of cytochrome P4503A (CYP3A) activity and gastrointestinal drug transport: insights from methadone interactions with ritonavir/indinavir.Maternal methadone dose, placental methadone concentrations, and neonatal outcomes.The effect of grapefruit juice on drug disposition.CYP2B6: new insights into a historically overlooked cytochrome P450 isozymeExpansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19Methadone-Associated Prolongation of the QTc Interval at Doses Used for Chronic Pain.Methadone dose in heroin-dependent patients: role of clinical factors, comedications, genetic polymorphisms and enzyme activityDifferences in Methadone Metabolism by CYP2B6 VariantsSurvey of methadone-drug interactions among patients of methadone maintenance treatment program in Taiwan.Cyclosporine-inhibitable cerebral drug transport does not influence clinical methadone pharmacodynamics.Dosing and monitoring of methadone in pregnancy: literature review.Methadone Pharmacogenetics: CYP2B6 Polymorphisms Determine Plasma Concentrations, Clearance, and MetabolismOpioid analgesics-related pharmacokinetic drug interactions: from the perspectives of evidence based on randomized controlled trials and clinical risk managementPharmacologic evidence to support clinical decision making for peripartum methadone treatment.Perioperative pharmacokinetics of methadone in adolescents.Rapid clinical induction of hepatic cytochrome P4502B6 activity by ritonavirMethadone metabolism and clearance are induced by nelfinavir despite inhibition of cytochrome P4503A (CYP3A) activity.Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities.Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: I. Evidence against CYP3A mediation of methadone clearance.Lack of indinavir effects on methadone disposition despite inhibition of hepatic and intestinal cytochrome P4503A (CYP3A).Pharmacokinetic interactions between buprenorphine and antiretroviral medications.
P2860
Q24649164-327E16EF-EFD1-43D1-A60C-842C7C1021DAQ26797376-0E7E065A-1624-4993-97B0-2DE0A29362EEQ27692040-1B495B74-ECDB-4B67-A3ED-2F529EF6BDDFQ28075979-CD1AA0F4-9996-4749-86CC-E97E9D417762Q28078857-3B38CDAC-00A4-4858-A975-EEAA3F3A1BAAQ30393865-7F5C4656-DE8A-4EE0-89EA-71F907FEA1F1Q30456107-56DBBE12-51A7-4340-A537-F9BC1CF35171Q33612033-2F07411D-E50A-4056-9212-C8147FBF318FQ33801821-ADDE042D-2375-42D2-B2DD-265D7C148A2EQ33835424-04664C8E-048B-43BB-AB8B-63BC167507CFQ33870389-AD088864-4037-4820-B474-9A438DC6592BQ33903933-F94ACE48-A9F9-4BDD-B22A-B25B3CD9C3B3Q34034583-AB06E5CD-5FE2-469D-B365-D6A72AA063F3Q34179339-C46166A9-576B-4F04-BC68-6EC158BBF911Q34359979-004FA502-F361-46B3-AD99-29C5BF8E9A9BQ34424648-E5D2517F-6E9B-431D-860A-AECF46E700A8Q34487284-D848D3E5-7FF7-47C1-B9C2-ACDDA95551E0Q34573885-39977675-2677-4CE5-9239-E0CCF0198637Q34583462-C0AED0C0-667C-4F71-8EE8-FA7A0B300BE6Q34604652-05BC0961-7A4A-4612-BE66-B57DC94EE6B0Q34626408-9FFBD593-F66F-4A8A-8C9D-572CC87187F3Q34764136-5D52C5BA-FE96-4B51-B024-FD73809C09B1Q34824471-052C0C88-B75C-4B37-9753-818D84B0000CQ35211432-48960C32-9A1B-4CB7-BDFA-7ECAD74C999CQ35283546-D8EB51C3-B005-430E-8648-454B77BE2253Q35684822-18BD0B0C-6B02-42A3-96DC-B37F13657059Q35745266-4F64E0D8-449D-4BAC-8967-5872C0CA780FQ36027332-D5DE4EF4-FB1A-4788-A7C4-E651AA3978C5Q36036200-C75E5E33-4F4A-421E-83AB-49CD4C86B49CQ36337610-0E9E3133-E224-42D4-91A9-DBA5C92C3B35Q36342286-D6DEA1F3-9407-48C1-ADEB-F040757E5227Q36392325-7BA6EFD5-16B7-48D8-A505-A61F14561515Q36511123-C2F13556-1449-45E5-B572-738151648EB3Q36578070-C4D60B68-D3F5-41F4-B9C3-D823995AFF9FQ36593838-49217998-6D7A-4C2A-9550-F991CC80F787Q36637864-AF063A81-B6D6-4923-9633-BEC4B25BB4E4Q36641870-89F13A6F-3650-4329-A9AD-09F988528B94Q36641884-41DD7744-6D28-458D-8780-BB5DDE2BC647Q36652680-A8C1B234-F70D-45A2-A1C2-07237DF69515Q36655057-94135F45-4E7B-4478-9D75-79079CD52CC1
P2860
Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone.
description
2004 nî lūn-bûn
@nan
2004 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Role of hepatic and intestinal ...... d miotic effects of methadone.
@ast
Role of hepatic and intestinal ...... d miotic effects of methadone.
@en
Role of hepatic and intestinal ...... d miotic effects of methadone.
@nl
type
label
Role of hepatic and intestinal ...... d miotic effects of methadone.
@ast
Role of hepatic and intestinal ...... d miotic effects of methadone.
@en
Role of hepatic and intestinal ...... d miotic effects of methadone.
@nl
prefLabel
Role of hepatic and intestinal ...... d miotic effects of methadone.
@ast
Role of hepatic and intestinal ...... d miotic effects of methadone.
@en
Role of hepatic and intestinal ...... d miotic effects of methadone.
@nl
P2093
P1476
Role of hepatic and intestinal ...... d miotic effects of methadone.
@en
P2093
Christine Hoffer
Dale Whittington
Evan D Kharasch
Pamela Sheffels
P304
P356
10.1016/J.CLPT.2004.05.003
P407
P577
2004-09-01T00:00:00Z